Abstract: A method of installing a slide fastener assembly in a thin shell garment includes: providing a slide fastener chain comprised of two interlocked rows of teeth, each row of teeth being attached to a cord bundle of a respective slide fastener tape; removing the interlocked rows of teeth from a portion of the slide fastener chain, thereby defining a length of the slide fastener chain without teeth; introducing a reinforcing film to the cord bundles, at a location along the length of the slide fastener chain without teeth, to shape the cord bundles for accommodation of a pin and box assembly; cutting the slide fastener chain at a film-reinforced location along the length of the slide fastener chain without teeth, thereby defining a semi-finished slide fastener assembly terminating in a film-reinforced end; and attaching the semi-finished slide fastener assembly to one or more panels of a thin shell garment.

Abstract: A cargo transport system includes a cassette for transporting a workpiece and dolly for transporting the cassette. The dolly includes a dolly frame and at least one wheel attached to the dolly frame for supporting the dolly on a surface. A track plate is attached to the dolly frame. The cassette is moveably mountable on the dolly and includes a cassette frame having first and second cassette conveyors engagable with the dolly for moveably supporting the cassette on the dolly. A first drive wheel is attached to the cassette frame between the first and second cassette conveyors. The first drive wheel is rotatable about a first axis of rotation and is operable for moving the cassette along a path-of-travel relative to the dolly. A location of the first axis of rotation is continuously adjustable relative to the cassette frame as the cassette moves along the path-of-travel.

Abstract: A cargo transport system includes a cassette for transporting a workpiece and dolly for transporting the cassette. The dolly includes a dolly frame and at least one wheel attached to the dolly frame for supporting the dolly on a surface. A track plate is attached to the dolly frame. The cassette is moveably mountable on the dolly and includes a cassette frame having first and second cassette conveyors engagable with the dolly for moveably supporting the cassette on the dolly. A first drive wheel is attached to the cassette frame between the first and second cassette conveyors. The first drive wheel is rotatable about a first axis of rotation and is operable for moving the cassette along a path-of-travel relative to the dolly. A location of the first axis of rotation is continuously adjustable relative to the cassette frame as the cassette moves along the path-of-travel.

Abstract: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.

Abstract: Non-mammalian, transgenic animals, e.g., flies, that include a RAS transgene, are provided. Also provided are methods of using the subject transgenic non-mammalian animals to identify compounds having activity with respect to cellular proliferative, such as neoplastic, diseases.

Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.

Abstract: Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.

Abstract: A method of installing a slide fastener assembly in a thin shell garment includes: providing a slide fastener chain comprised of two interlocked rows of teeth, each row of teeth being attached to a cord bundle of a respective slide fastener tape; removing the interlocked rows of teeth from a portion of the slide fastener chain, thereby defining a length of the slide fastener chain without teeth; introducing a reinforcing film to the cord bundles, at a location along the length of the slide fastener chain without teeth, to shape the cord bundles for accommodation of a pin and box assembly; cutting the slide fastener chain at a film-reinforced location along the length of the slide fastener chain without teeth, thereby defining a semi-finished slide fastener assembly terminating in a film-reinforced end; and attaching the semi-finished slide fastener assembly to one or more panels of a thin shell garment.

Abstract: Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives.

Abstract: An attachable collar arrangement for a down hole apparatus that includes a collar member releasably insertable into a cutaway section disposed circumferentially around a tool joint or other down hole apparatus. The collar member is stabilized in position within the cutaway section by means of a stabilizing insert member which is releasably inserted between at least two sections of the collar member, and removably secured into a member insert receptacle disposed upon the tool joint or other down hole apparatus. Wear and erosion are directed to the collar member during drilling operations and the tool joint or down hole apparatus is thereby protected. The collar member is expediently replaceable when needed and drilling operations are extended over the life of particular drilling equipment to which the device is installed.

Abstract: Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives.

Abstract: The present invention relates to compositions that comprise an anti-S1P monoclonal antibody, antibody fragment, or derivative in a carrier, particularly a buffered, hypertonic aqueous solution, as well as to kits containing such compositions, and methods for using such compositions for treatment of diseases and conditions associated with S1P.

Abstract: Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.

Abstract: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.

Abstract: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.

Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.

Abstract: Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives.

Abstract: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2?-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.

Abstract: Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives.

Abstract: Compositions and methods for making and using humanized anti-LPA monoclonal antibodies, and fragments and derivatives thereof, are described.